SRZN, SRZNW · CIK 0001824893 · operating
A biotechnology company headquartered in South San Francisco, Surrozen discovers and develops antibody-based therapeutics targeting the Wnt signaling pathway for tissue repair applications. The company focuses on selective modulation of Frizzled 4 (Fzd4) and related pathways to address diseases across multiple organ systems, including the retina, cornea, liver, intestine, kidney, lung, and central nervous system.
The company's pipeline centers on several lead candidates. SZN-814 combines Fzd4 agonism with VEGF antagonism for diabetic macular edema and age-related macular degeneration. SZN-8143 adds interleukin-6 targeting to this combination for similar retinal indications. SZN-113 targets Fuchs' endothelial corneal dystrophy and geographic atrophy, while SZN-413 is a bi-specific antibody for retinal vascular diseases. The company maintains a collaboration with Boehringer Ingelheim to develop and commercialize Fzd4 bi-specific antibodies, and a research agreement with TCGFB, Inc. for transforming growth factor beta targeting in pulmonary fibrosis.
Surrozen operates as a private clinical-stage company with approximately 40 full-time employees. The company was founded in 2015 and is incorporated in Delaware.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-21.67 | $-21.67 | -1.6% | |
| 2023 | $-21.33 | $-21.33 | -1951.0% | |
| 2022 | $-1.04 | $-1.04 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |